4th BioVaria Sets Records for Attendance and Commercial Opportunities

BioVaria Spin-off Award goes to Dynamic Biosensors

Munich, (PresseBox) - Over 170 biopharma dealmakers, investors, scientists and technology transfer professionals gathered on 24 May in Munich for BioVaria 2011. Their goal was to initiate partnerships for the development of promising life-science projects originating from leading public research institutions and universities from all over Europe.

Around 70 licensable projects in the fields of cancer, autoimmunity, inflammation, cardiovascular and other major diseases were presented by 15 technology transfer organizations and their 37 academic partner institutes from eight European nations. Each presentation stream was followed by lively discussions between the inventors and potential licensees in the exhibition room.

'BioVaria is an excellent event for pharma companies to learn about discoveries and new developments from academic research," said Paul Leijten, MD, Senior Partnering Director at TEVA. 'We expect to initiate new collaborations here. I have already met some scientists who presented very interesting projects I did not know about before.'

BioVaria's Spin-off Panel was also well received among business developers and venture capitalists. In a round-table setting, five selected spin-offs were briefly introduced and then challenged with exacting questions by a jury of seasoned life-science executives and investors. The most convincing candidate in terms of team, technology and business concept was selected as winner of the BioVaria Spin-off Award, worth EUR 1,000 plus professional legal consulting. This year, the award went to Dynamic Biosensors, a spin-off from the Technische Universität München (TUM) and Fujitsu Laboratories Ltd. that develops and commercializes a new technology for the real-time analysis of biomolecular interactions.

'The Panel is a rare opportunity for spin-offs to make a pitch in a realistic situation. The tight timelines force them to nail their points exactly', said Samuel Ogunsalu, Principal Executive, Commercial Development at Queen Mary Innovation, who moderated this year's Spin-off Panel. 'And for the audience, it is a great chance to learn about some really dynamic technologies and entrepreneurial teams.'

Altogether, the portfolio of commercial opportunities presented during BioVaria has grown by some 30%, compared to 2010. Moreover, this year's technologies were further advanced on average compared with previous years.

'This is the strongest portfolio of licensing and investment opportunities since BioVaria was launched four years ago,' Christian Stein, CEO of Ascenion comments. 'In order to secure BioVaria's sustained success we will work closely with our partners to further increase the maturity of the projects presented using a two-tier strategy: first, by including further leading technology transfer offices as BioVaria partners while maintaining our strict project selection criteria, and second, by maturing promising academic projects in a market-oriented way using the Spinnovator and other public-private partnerships that have been established over the years in Europe.'

All technologies and spin-offs presented during BioVaria 2011 are available online at www.biovaria.org

About BioVaria
BioVaria is a pan-European, biopharmaceutical showcasing event jointly organized by Ascenion and a broad range of technology transfer organizations. For both industry and academia, it provides a unique platform to meet and initiate partnerships for the development of promising early-stage projects.

Key features of BioVaria:
- One interactive day providing a comprehensive overview of licensing and investment opportunities emanating from publicly funded research in Europe
- Focus on commercially attractive, patent-protected technologies covering research tools, diagnostic and therapeutic candidates in the fields of cancer, infectious diseases, metabolism, autoimmune and neurodegenerative disorders, and other disease areas
- Presentation of 70 technologies and selected spin-offs
- Unique format combining 10-min oral presentations with an interactive spin-off panel and an all-day poster exhibition
- Ample space to discuss scientific details face-to-face with the inventors

Ascenion GmbH, Austria Wirtschaftsservice Gesellschaft mbH, Bayerische Patentallianz GmbH, BDC - The Business Development Company GmbH, BTO - Bergen Teknologioverføring AS, CRP-Santé, EMBLEM Technology Transfer GmbH, FIST S.A. - France Innovation Scientifique & Transfert, Hellenic Bio Cluster, Inserm Transfert S.A. , ipal GmbH, K.U. Leuven Research & Development, Max-Planck-Innovation GmbH, Nationales Genomforschungsnetz, PROvendis GmbH

BioM Biotech Cluster Development GmbH, Bayer Healthcare, MSD Sharp & Dohme GmbH, MLaw Group, TEVA Pharmaceutical Industries Ltd., Bachem AG, Boehringer Ingelheim, Hertin - IP Law Firm, TVM Capital GmbH, Vesalius Biocapital, Vossius & Partner

Communication partner:

Media partners:
Biotech finances, Innovaro Pharmalicensing, MedTrack, transkript

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.

I want to subscribe to the gratis press mail and have read and accepted the conditions.